BACKGROUND: Neurofilament light chain (NFL) and chitinase-3-like-1 (CHI3L1) concentrations in cerebrospinal fluid (CSF) may have prognostic value in clinically isolated syndromes (CIS) and relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES: To compare the prognostic value of CSF concentrations of NFL and CHI3L1 in newly diagnosed CIS and RRMS patients. METHODS: NFL and CHI3L1 were measured in CSF in 177 newly diagnosed patients with CIS or RRMS who were followed clinically for a mean of 5.7 years. RESULTS: At baseline CSF concentrations of NFL correlated with CSF concentrations of CHI3L1, relapses in the previous year, time from last relapse, and the Expanded Disability Status Scale (EDSS) score. CSF concentrations of NFL and CHI3L1 were both associated with increased relapse risk during the first 2 years in univariate analyses, but only the CSF concentration of NFL was independently associated with relapse risk in a multivariable analysis. There was no relationship between CSF concentrations of NFL or CHI3L1 and risk of conversion to secondary progressive MS or development of disability. CONCLUSION: CSF concentrations of NFL are associated with 2-year relapse risk but not with disease progression or clinical worsening in newly diagnosed CIS and RRMS patients. This may be due to confounding by the effect of disease-modifying therapies.
BACKGROUND: Neurofilament light chain (NFL) and chitinase-3-like-1 (CHI3L1) concentrations in cerebrospinal fluid (CSF) may have prognostic value in clinically isolated syndromes (CIS) and relapsing-remitting multiple sclerosis (RRMS). OBJECTIVES: To compare the prognostic value of CSF concentrations of NFL and CHI3L1 in newly diagnosed CIS and RRMS patients. METHODS:NFL and CHI3L1 were measured in CSF in 177 newly diagnosed patients with CIS or RRMS who were followed clinically for a mean of 5.7 years. RESULTS: At baseline CSF concentrations of NFL correlated with CSF concentrations of CHI3L1, relapses in the previous year, time from last relapse, and the Expanded Disability Status Scale (EDSS) score. CSF concentrations of NFL and CHI3L1 were both associated with increased relapse risk during the first 2 years in univariate analyses, but only the CSF concentration of NFL was independently associated with relapse risk in a multivariable analysis. There was no relationship between CSF concentrations of NFL or CHI3L1 and risk of conversion to secondary progressive MS or development of disability. CONCLUSION: CSF concentrations of NFL are associated with 2-year relapse risk but not with disease progression or clinical worsening in newly diagnosed CIS and RRMS patients. This may be due to confounding by the effect of disease-modifying therapies.
Authors: Adriel S Moraes; Vinicius O Boldrini; Alliny C Dionete; Marilia D Andrade; Ana Leda F Longhini; Irene Santos; Amanda D R Lima; Veronica A P G Silva; Rafael P C Dias Carneiro; Raphael P S Quintiliano; Breno B Ferrari; Alfredo Damasceno; Fernando Pradella; Alessandro S Farias; Charles P Tilbery; Renan B Domingues; Carlos Senne; Gustavo B P Fernandes; Felipe von Glehn; Carlos Otavio Brandão; Carla R A V Stella; Leonilda M B Santos Journal: Front Cell Neurosci Date: 2021-07-26 Impact factor: 5.505
Authors: Sara Gil-Perotin; Jessica Castillo-Villalba; Laura Cubas-Nuñez; Raquel Gasque; David Hervas; Josep Gomez-Mateu; Carmen Alcala; Francisco Perez-Miralles; Francisco Gascon; Jose Andres Dominguez; Bonaventura Casanova Journal: Front Neurol Date: 2019-09-23 Impact factor: 4.003
Authors: Tomas Uher; Sabine Schaedelin; Barbora Srpova; Christian Barro; Niels Bergsland; Michael Dwyer; Michaela Tyblova; Karolina Vodehnalova; Pascal Benkert; Johanna Oechtering; David Leppert; Yvonne Naegelin; Jan Krasensky; Manuela Vaneckova; Eva Kubala Havrdova; Ludwig Kappos; Robert Zivadinov; Dana Horakova; Jens Kuhle; Tomas Kalincik Journal: Neurol Neuroimmunol Neuroinflamm Date: 2020-04-09
Authors: Tatiana Plavina; Carol M Singh; Dipen Sangurdekar; Carl de Moor; Bob Engle; Arie Gafson; Jaya Goyal; Elizabeth Fisher; Suzanne Szak; Revere P Kinkel; Alfred W Sandrock; Ray Su; Bernd C Kieseier; Richard A Rudick Journal: JAMA Netw Open Date: 2020-11-02
Authors: Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei Journal: Int J Mol Sci Date: 2022-03-21 Impact factor: 5.923